-
-
-
-
-
-
-
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
-
-
-
-
-
-
-
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
-
-
-
-
-
-
-
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
-
-
-
-
-
-
-
UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
-
-
-
-
-
-
-
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
-
-
-
-
-
-
-
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
-
-
-
-
-
-
-
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
-
1,160,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

